{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:43:04Z","timestamp":1792021384054,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["122Z163"],"award-info":[{"award-number":["122Z163"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","award":["4162"],"award-info":[{"award-number":["4162"]}],"id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.tips.2023.07.006","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:46:00Z","timestamp":1692254760000},"page":"705-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Muscle wasting: emerging pathways and potential drug targets"],"prefix":"10.1016","volume":"44","author":[{"given":"Aylin","family":"Domaniku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevval Nur","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-9913","authenticated-orcid":false,"given":"Serkan","family":"Kir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2023.07.006_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2023.07.006_bb0010","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","article-title":"Cachexia: a systemic consequence of progressive, unresolved disease","volume":"186","author":"Ferrer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.07.006_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-pharmtox-010818-021041","article-title":"Muscle wasting diseases: novel targets and treatments","volume":"59","author":"Furrer","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2023.07.006_bb0020","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2023.07.006_bb0025","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-skipping in Duchenne muscular dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.tips.2023.07.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.07.006_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in Duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.07.006_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41577-021-00624-w","article-title":"The interplay of immunology and cachexia in infection and cancer","volume":"22","author":"Baazim","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2023.07.006_bb0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06047-y","article-title":"EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia","volume":"617","author":"Bilgic","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2023.07.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia","volume":"42","author":"Kim-Muller","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2023.07.006_bb0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41467-020-20123-1","article-title":"Mechanisms of muscle atrophy and hypertrophy: implications in health and disease","volume":"12","author":"Sartori","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia \u2013 understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argiles","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small-cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0075","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10637-015-0226-6","article-title":"Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small-cell lung cancer","volume":"33","author":"Hong","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.tips.2023.07.006_bb0085","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0095","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/s41598-022-19401-3","article-title":"Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil\/folinic acid in advanced pancreatic ductal adenocarcinoma","volume":"12","author":"Gong","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2023.07.006_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rco2.24","article-title":"JAK inhibitors suppress cancer cachexia-associated anorexia and adipose wasting in mice","volume":"3","author":"Arora","year":"2020","journal-title":"JCSM Rapid Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0105","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","article-title":"JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia","volume":"303","author":"Bonetto","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2023.07.006_bb0110","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.1074\/jbc.M115.638411","article-title":"A key role for leukemia inhibitory factor in C26 cancer cachexia","volume":"290","author":"Seto","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2023.07.006_bb0115","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1074\/jbc.M115.641514","article-title":"Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia","volume":"290","author":"Silva","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2023.07.006_bb0120","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12935-021-02332-w","article-title":"Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia","volume":"21","author":"Xie","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.tips.2023.07.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2023.07.006_bb0130","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tips.2023.07.006_bb0135","article-title":"Activated Oncostatin M signaling drives cancer-associated skeletal muscle wasting","author":"Domaniku","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.tips.2023.07.006_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tips.2023.07.006_bb0145","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3390\/cells11172671","article-title":"Transforming growth factor-beta signaling in cancer-induced cachexia: from molecular pathways to the clinics","volume":"11","author":"Balsano","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tips.2023.07.006_bb0150","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jcsm.12461","article-title":"The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy","volume":"10","author":"Zhong","year":"2019","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.07.006_bb0160","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41467-022-32135-0","article-title":"Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer","volume":"13","author":"Queiroz","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0165","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","article-title":"First-in-human Phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors","volume":"25","author":"Tao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2023.07.006_bb0170","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0175","doi-asserted-by":"crossref","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","article-title":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis","volume":"95","author":"Sivakumar","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2023.07.006_bb0180","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2023.07.006_bb0185","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2023.07.006_bb0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","article-title":"Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial","volume":"199","author":"Polkey","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tips.2023.07.006_bb0195","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(21)00084-2","article-title":"Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a\/b trial","volume":"2","author":"Hofbauer","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.tips.2023.07.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20836","article-title":"Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial","volume":"3","author":"Rooks","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tips.2023.07.006_bb0205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mce.2017.02.031","article-title":"Androgen-mediated regulation of skeletal muscle protein balance","volume":"447","author":"Rossetti","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tips.2023.07.006_bb0215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0220","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12603-013-0335-x","article-title":"A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia","volume":"17","author":"Papanicolaou","year":"2013","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.tips.2023.07.006_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tips.2023.07.006_bb0230","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/clinem\/dgab361","article-title":"A selective androgen receptor modulator (OPK-88004) in prostate cancer survivors: a randomized trial","volume":"106","author":"Pencina","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2023.07.006_bb0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thorax-2021-218360","article-title":"Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial","volume":"78","author":"Mohan","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.tips.2023.07.006_bb0240","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.tips.2023.07.006_bb0245","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0250","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.clnme.2012.07.004","article-title":"Randomized study of the efficacy and safety of SUN11031 (synthetic human ghrelin) in cachexia associated with chronic obstructive pulmonary disease","volume":"7","author":"Levinson","year":"2012","journal-title":"e-SPEN J"},{"key":"10.1016\/j.tips.2023.07.006_bb0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0260","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2023.07.006_bb0265","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jcsm.12675","article-title":"The regulatory approval of anamorelin for treatment of cachexia in patients with non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers","volume":"12","author":"Wakabayashi","year":"2021","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0275","first-page":"497","article-title":"Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study","volume":"30","author":"Yennurajalingam","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0280","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1038\/s41598-021-88438-7","article-title":"\u03b22-Adrenergic receptor agonist counteracts skeletal muscle atrophy and oxidative stress in uremic mice","volume":"11","author":"Higashihara","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2023.07.006_bb0285","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcsm.12395","article-title":"Insulin\/IGF1 signalling mediates the effects of \u03b2(2)-adrenergic agonist on muscle proteostasis and growth","volume":"10","author":"Gon\u00e7alves","year":"2019","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0290","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.29930","article-title":"Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and beta-2 agonist","volume":"138","author":"Toledo","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0295","first-page":"1269","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tips.2023.07.006_bb0300","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcsm.12126","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small-cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)","volume":"7","author":"Stewart Coats","year":"2016","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0305","first-page":"680","article-title":"Repurposing Drugs in Oncology (ReDO) \u2013 propranolol as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.tips.2023.07.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106868118","article-title":"Activation of the hypothalamic\u2013pituitary\u2013adrenal axis by exogenous and endogenous GDF15","volume":"118","author":"Cimino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.07.006_bb0315","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2023.07.006_bb0320","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","article-title":"Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice","volume":"26","author":"Suriben","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2023.07.006_bb0325","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa007","article-title":"GDF15: a hormone conveying somatic distress to the brain","volume":"41","author":"Lockhart","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tips.2023.07.006_bb0330","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1038\/s41467-022-32905-w","article-title":"Sirtuin 6 inhibition protects against glucocorticoid-induced skeletal muscle atrophy by regulating IGF\/PI3K\/AKT signaling","volume":"13","author":"Mishra","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0335","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1016\/j.cmet.2023.05.008","article-title":"Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia","volume":"35","author":"Ferrer","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2023.07.006_bb0340","doi-asserted-by":"crossref","first-page":"E6780","DOI":"10.1073\/pnas.1512968112","article-title":"Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program","volume":"112","author":"Morrison-Nozik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.07.006_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155972","article-title":"Exogenous Oncostatin M induces cardiac dysfunction, musculoskeletal atrophy, and fibrosis","volume":"159","author":"Jengelley","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.tips.2023.07.006_bb0350","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbrc.2019.06.143","article-title":"Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation","volume":"516","author":"Miki","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0355","doi-asserted-by":"crossref","first-page":"R132","DOI":"10.1186\/ar4312","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials","volume":"15","author":"Choy","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2023.07.006_bb0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/biomedicines7040095","article-title":"Oncostatin M in the regulation of connective tissue cells and macrophages in pulmonary disease","volume":"7","author":"Richards","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.tips.2023.07.006_bb0365","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/MCB.24.4.1608-1613.2004","article-title":"Myodegeneration in EDA-A2 transgenic mice is prevented by XEDAR deficiency","volume":"24","author":"Newton","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tips.2023.07.006_bb0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbrc.2015.08.019","article-title":"XEDAR activates the non-canonical NF-kappaB pathway","volume":"465","author":"Verhelst","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0375","article-title":"Glucocorticoids increase skeletal muscle NF-kappaB inducing kinase (NIK): links to muscle atrophy","volume":"4","author":"Fry","year":"2016","journal-title":"Phys. Rep."},{"key":"10.1016\/j.tips.2023.07.006_bb0380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10528","article-title":"Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63","volume":"5","author":"von Grabowiecki","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.tips.2023.07.006_bb0385","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/1471-2164-12-602","article-title":"Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model","volume":"12","author":"Llano-Diez","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.tips.2023.07.006_bb0390","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1152\/physiolgenomics.00022.2013","article-title":"Altered gene expression patterns in muscle ring finger 1 null mice during denervation- and dexamethasone-induced muscle atrophy","volume":"45","author":"Furlow","year":"2013","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.tips.2023.07.006_bb0395","article-title":"Increased expression of ectodysplasin A2 receptor EDA2R is the most remarkable and ubiquitous aging-related transcriptional hallmark","author":"Barbera","year":"2021","journal-title":"Researchgate"},{"key":"10.1016\/j.tips.2023.07.006_bb0400","first-page":"9393","article-title":"Single nuclei profiling identifies cell specific markers of skeletal muscle aging, frailty, and senescence","volume":"14","author":"Perez","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.tips.2023.07.006_bb0405","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molmed.2019.02.005","article-title":"NIK as a druggable mediator of tissue injury","volume":"25","author":"Valino-Rivas","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2023.07.006_bb0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41467-017-02672-0","article-title":"NF-kappaB inducing kinase is a therapeutic target for systemic lupus erythematosus","volume":"9","author":"Brightbill","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0415","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.18632\/oncotarget.2128","article-title":"Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB","volume":"5","author":"Demchenko","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2023.07.006_bb0420","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1096\/fj.201600840R","article-title":"A small-molecule inhibitor of NF-kappaB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury","volume":"31","author":"Ren","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2023.07.006_bb0425","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1021\/acs.jmedchem.0c00055","article-title":"Identification of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as novel, potent, and selective NF-kappaB inducing kinase (NIK) inhibitors for the treatment of psoriasis","volume":"63","author":"Zhu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.07.006_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115316","article-title":"A novel inhibitor of NF-kappaB-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice","volume":"135","author":"Takakura","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.tips.2023.07.006_bb0435","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10753-023-01820-7","article-title":"NF-kappaB-inducing kinase provokes insulin resistance in skeletal muscle of obese mice","volume":"46","author":"Chen","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.tips.2023.07.006_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.597675","article-title":"Inflammation and skeletal muscle wasting during cachexia","volume":"11","author":"Webster","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.tips.2023.07.006_bb0445","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1038\/s41467-023-40024-3","article-title":"Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer","volume":"14","author":"Babic","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.07.006_bb0450","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13539-014-0161-y","article-title":"Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014","volume":"5","author":"Morley","year":"2014","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2023.07.006_bb0455","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bpa.12350","article-title":"The role of skeletal muscle in amyotrophic lateral sclerosis","volume":"26","author":"Loeffler","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.tips.2023.07.006_bb0460","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jcsm.12633","article-title":"Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?","volume":"11","author":"Dolly","year":"2020","journal-title":"J. Cachexia. Sarcopenia Muscle"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:51:49Z","timestamp":1777495909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614723001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0165614723001682"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2023.07.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscle wasting: emerging pathways and potential drug targets","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2023.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}